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Background: Achieving good glycemic control is of paramount importance in the reduction of diabetes mellitus
(DM) associated morbidity and mortality. Insulin plays a key role in the management of DM but unfortunately whilst
some healthcare providers present insulin as a treatment of last resort , patients on insulin often have insulin
related issues such as needle phobias, fear of hypoglycaemia, weight gain and in developing countries, costs. This
Report aims at assessing insulin prescription pattern, insulin costs and issues associated with adherence.
Methods: This was a Cross-sectional observation Study whereby 160 patients with DM who were on insulin solely
or in combination with oral hypoglycaemic agents were recruited over a 6 month period. Information obtained
from the Study subjects pertained to their histories of DM, types of insulin, insulin costs, adherence issues and
insulin delivery devices. Long and short term glycaemic control were determined and evaluated for possible
relation to insulin adherence. Test statistics used were chi square, t test and binary regression.
Results: Insulin adherence was noted in 123-77% of the Study subjects and this was comparable between persons
with type 1 DM and those with type 2 DM. The mean glycosylated haemoglobin values were significantly higher in
those who admitted to non insulin adherence compared to those who adhered to their insulin regimen (9.7% (2.3)
Vs 8.6% (2.1), p = 0.01). Reasons proffered by Respondents for non insulin adherence included high costs-15(41%),
inconvenience −15 (41%) and needle pain-79)18%. A greater proportion of persons who self injected insulin
adhered to insulin prescriptions compared to those who did not self inject and thus had better glycaemic control.
Shorter duration of DM and older age were found to be predictors of adherence to insulin prescription.
The monthly mean costs of insulin for those who earned an income was 5212.8 Nigerian naira which is equivalent
to 33.1 US dollars and we estimated that persons on a minimum wage would spend 29% of their monthly income
on the procurement of insulin.
Conclusions: Health related costs, age, duration of DM and insulin associated side effects are some of the factors
implicated in adherence to insulin prescription.Background
The prevalence of diabetes mellitus (DM), is on the rise
worldwide and this is more so in the developing coun-
tries which unfortunately are already overburdened by a
high disease burden arising from communicable dis-
eases. It is estimated that by the year 2030, over 70% of
people with diabetes will reside in developing countries
[1]. The burden of DM is unacceptably high in the
developing countries of the world with oft documented
high morbidity and mortality rates. Good glycaemic* Correspondence: oogbera@yahoo.co.uk
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distribution, and reproduction in any mediumcontrol is of utmost importance in reducing the burden
of disease attributable to diabetes mellitus. Optimal
management of DM is a key factor in reducing the afore
mentioned scenario. Management of DM includes the
employment of non pharmacological and pharmaco-
logical interventions of which insulin therapy plays a
prominent role. Insulin therapy is used in the manage-
ment of diabetes mellitus of all types and the need for
insulin depends on the balance between insulin secretion
and insulin resistance. Effective usage of insulin in the
management of glycaemia remains a challenge in devel-
oping countries like Nigeria. In a Nigerian report, the
percentage of persons with type 2 DM documented to
be on insulin therapy was 15.4% with 5.4% on insulinntral Ltd. This is an Open Access article distributed under the terms of the
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oral hypoglycaemic agents [2].
In most developing countries, the mainstay of insulin
delivery is single or multiple daily subcutaneous injec-
tions and commonly used insulin delivery devices in-
clude insulin syringes and pens. Insulin therapy remains
widely unacceptable amongst patients with DM and rea-
sons for this scenario range from needle phobia, costs
and inconvenience of daily injections.
There is a plethora of terminologies used with refer-
ence to medication -taking behaviour and these include
“adherence”, “concordance”, “persistence” and “compli-
ance”. Adherence is defined as ‘the extent to which a
person’s behavior (in terms of taking medications, fol-
lowing diets, or executing lifestyle changes) coincides
with medical or health advice [3]. Rates of refilling for
prescriptions have been used as a method of measuring
adherence and is also another means of testing “persist-
ence”. Persistence is a relatively recent terminology that
describes the duration of continuous medication use and
is of limited value in clinical practice. This is because it
refers more to how frequently a patient will collect a
prescription for a certain treatment rather than whether
it is actually taken or not [4]. Compliance is defined as:
“the extent to which the patient follows the health pro-
fessionals’ advice and takes the treatment” [4]. As
opposed to adherence, compliance is rather one of pas-
sivity on the part of the patient and does not take cogni-
sance of the patient having a say in the management of
the disease condition. Concordance is defined as: “agree-
ment between the patient and healthcare professional,
reached after negotiation that respects the beliefs and
wishes of the patient in determining whether, when and
how their medicine is taken and describes an agreement
drawing upon the experiences of both provider and pa-
tient [4]. We however decided to use the term adherence
in our Report especially as it is more suitable to our
Study compared to the other stated terms.
The objective of this Report is to document the pat-
tern of insulin prescription, regimen, costs and attendant
problems associated with its use. We also attempt to
evaluate for factors affecting insulin adherence.Methods
This was a Cross sectional observational study carried
out at the Diabetic Centre of the Lagos State University
Teaching Hospital, (LASUTH), Lagos State. Persons liv-
ing with diabetes mellitus who were on insulin treatment
(for at least a period of one month) solely or in combin-
ation with oral hypoglycaemic agents and who gave their
consent were recruited.
Ethical approval for the study was obtained from the
Lagos State University Teaching Hospital.Participants provided information on their diabetes
history, management and problems associated with man-
agement. The type of insulin in use, the number of daily
injections, issues with adherence were ascertained from
the Case folders, patient interview and prescriptions.
Gainful employment where present was noted and the
monthly income for those who earned a salary was
documented.
Clinical examination was carried out basically to deter-
mine the anthropometric indices.
Long term and short term glycaemic control was eval-
uated for using glycosylated haemoglobin and fasting
plasma glucose assessment respectively.
Good long term glycaemic control referred to HbA1c
level of ≤6.5% [5].
Short term glycaemic control referred to FPG levels of
≤110 mg% [5].
Type 2 DM-Patients were classified as having type 2
diabetes mellitus using clinical criteria such as a present/
prior history of usage of oral hypoglycaemic agents or
usage of combination of insulin and the oral hypogly-
caemic agents [6].
Type 1DM- This referred to patients who are pres-
ently on insulin and have been insulin requiring since
diagnosis [6].
Information on insulin adherence was provided by the
patients and their family members.
Insulin adherence was defined as “taking medication
as prescribed and/or agreed between the patients and
the health care provider over a period of one month”.
The “adherence rate” for the Study subjects referred to
the proportion of patients who used insulin as pre-
scribed over a period of one month.
Non adherence referred “not taking medication as pre-
scribed and/or agreed between the patients and the
health care provider over a period of one month”.
Insulin costs (direct cost) per month was determined
through patient’s interview. Information on the number
of vials or penfills of insulin and costs per month was
obtained from the patient. Costs of insulin were calcu-
lated in Nigerian Naira (NGN) and converted to US dol-
lars (USD) and the prevailing currency exchange rate
was 150NGN to 1USD.
The proportion of income spent on insulin was calcu-
lated by the following formula:
Mean insulin costs of those earning an income  100
Prevailing Nigerian Minimum wage
(The prevailing minimum wage was 18,000 NGN or
120 USD)
SPSS was used for statistical analyses and a p value
of ≤ 0.05 was deemed to be significant.
Table 1 Clinical characteristics of the Study Subjects
Parameter Mean (SD) Range
Age (years) 53 (13.6) 18.29
BMI (kgm2) 27 (5.7) 15.5-53.3
Waist circumference (cm) 77.8 (66.8) 38-133
Duration of DM (years) 10.3 (9.8) 0.4-35
Duration of insulin use (years) 4.2 (5.9) 0.1-31
Table 2 Pattern of insulin use
Type of insulin N (%)
Human Insulin
Fixed dose combination (30/70) 130 (81%)
Lente Insulin 14 (8%)
NPH Insulin 9 (6%)
Regular Insulin 3 (2%)
Insulin Analogues
Glargine 4 (3%)
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Of the 160 Respondents in this Report, females were
104 (65%) and males were 56 (35%). The mean age in
years was comparable in both genders (Females −53.6
(13.5) Vs Males −52.1 (13.8), p = 0.5).
Persons with type 1DM were 31 and type 2DM were
129 in number accounting for 19% and 81% respectively
of the Study population. About half (53%) of the persons
studied were gainfully employed and earned an income.
Well over half 122 (76.3%) of the subjects were married,
23 (14.4%) were divorced or widowed and 15 (9.3%)
were single. A breakdown of the cadre of educational
status is as listed: Non-literate 14 (8.7%), Primary
education-44 (27.5%), Secondary education-51 (31.9%),
Tertiary education −51 (31.9%).
The Clinical features of the Study population are
shown in Table 1.
Treatment types, administrative devices and dosing
frequency
Prior to insulin treatment, 126 (98%) of the Study sub-
jects were on oral hypoglycaemic agents and 3 (2%)
resorted to use of herbal remedies. With insulin treat-
ment, the pattern of treatment was such that of the
patients with type 2 DM, 118 (91%) were onFigure 1 Distribution of frequency of insulin dosing in persons
with DM.combinations of insulin and oral hypoglycaemic agents
and 11 (9%) were on sole insulin treatment.
Insulin dosing regimen ranged from once to four times
daily. The distribution of the dosing frequency of insulin
is shown in Figure 1.
Insulin administrative devices used were Insulin
syringes-113 (71%) and Insulin pens 47 (29%). The large
majority-150 (94%) of the subjects self inject insulin. A
total of 90-(56%) of the subjects practised self home glu-
cose monitoring.
Human Insulin was the commonly used insulin with
premixed preparations taking the lead. The pattern of
insulin use is shown in Table 2.
Hypoglycaemia was the most frequently documented
problems encountered by persons on insulin. Figure 2
depicts the frequency of problems associated with insu-
lin usage.
Insulin adherence
Insulin adherence was noted in 123-77% -of the Study
subjects and this was comparable between persons with
type 1 DM and those with type 2 DM. Long term good
glycaemic control was 52 (32%) of the patients. The
mean glycosylated haemoglobin values were significantly
higher in those who admitted to non insulin adherenceFigure 2 Problems associated with insulin use.
Table 3 Comparison of clinical and biochemical parameters in persons who adhered and those that did not adhere to
prescribed insulin regimens
Variable Insulin adherence Insulin non adherence p
Mean Hba1c (%) 8.6 (2.5) 10.1 (2.5) 0.008
Fasting plasma glucose (mg%) 165.5 (83.5) 205.6 (89.8) 0.02
Previous DM hospitalization 83 (68%) 18 (48.6%) 0.03
Gainfully employed 63 (52%) 22 (60%) 0.4
Family hx of DM 67 (55%) 22 (60%) 0.5
Self insulin injection 118 (96%) 32 (87%) 0.03
Self glucose monitoring 72 (59%) 18 (49%) 0.2
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(9.7% (2.3) Vs 8.6% (2.1), p = 0.01).
For the respondents who could not adhere to their
insulin regimens, reasons adduced for this scenario in-
clude the following; High costs-15(41%), inconvenience
−15(41%) and needle pain-79)18%. 77 (48.1%) persons
experienced problems with insulin injections and these
were Hypoglycaemia-51-(66.2%), Weight gain-19-(24.6%)
and Skin changes, hyperpigmentation and skin atrophy
−7-(9.2%)
A greater proportion of persons who self injected insu-
lin adhered to insulin prescriptions compared to those
who did not adhere. The mean indices of short and long
term glycaemic control were noted to be higher in per-
sons who did not adhere to insulin prescriptions. These
results are shown in Table 3.
Shorter duration of DM and older age were possible
predictors of insulin adherence. These results are shown
in Table 4. Insulin Adherence was comparable between
persons who were educated and those who had no form
of literacy (85% vs 76%, p = 0.3).
Insulin costs
The mean costs of insulin estimated for the Study sub-
jects was Nigerian Naira (NGN) 4534.9 (4742.7) and
USD29 (30). The calculated median insulin cost was
NGN 3, 400(USD21.6) and range were NGN 1120 to
NGN 40, 000 and USD 7.1 to USD 254.6 respectively.
About half-94(58%) of the Study subjects paid for theirTable 4 Evaluation of possible predictors of insulin
adherence
Variable Exp (B) interval 95% Confidence
interval
p
Duration of DM 0.9 0.88-0.99 0.03
Age 1.1 1.06-1.73 0.01
Educational status 1.2 0.23-6.23 0.8
Type of DM 2.7 0.8-9.25 0.1
Self payment 0.7 0.29-1.86 0.5
Gender 1.44 0.5-3.53 0.4
Gainful employment 1.1 0.5-2.4 0.7insulin themselves, -13(8%) had their insulin paid for by
their parents (this group of patients had type 1 DM), -10
(6%) had their insulin paid for by relations and 43-(27%)
had their insulin paid for by their children.
For those who earned a salary, the proportion of in-
come spent on insulin was determined to be 29%. A
summary of the income and costs of insulin of those who
paid for their insulin themselves are shown in Table 5.
Comparison of some clinical parameters with respect to
insulin use between persons with type 1 and those with
type 2 DM
Some clinical parameters compared between persons
with type 1 and those with type 2 DM are shown in
Table 6.
In the comparison of frequency of insulin injection in
persons with type 2 DM and those with type 1 DM, we
noted that more people with type1 DM injected insulin
twice a day compared with persons with type 2 DM. In
our Report we observed that only persons with type 2
DM were on a four times a day insulin regimen. These
results are shown in Figure 3.
Discussion
The role of insulin in the management of diabetes melli-
tus cannot be overemphasized and people with diabetes
use combinations of different types of insulin to better
control and manage their condition [7,8]. In this Report,
we note that the majority of persons with type 2 DM
who are on insulin therapy use insulin in varying combi-
nations with oral glucose lowering agents.
A third of the respondents reported omitting insulin
injections with the commonly documented reason for
this being the associated high costs of insulin. OftenTable 5 Income and Insulin costs for self paying patients
Variable Mean (SD) Median Range
Income (NGN) 63,319 (1386.1) 30,000 5000-1500000
Income (USD) 403 (8.7) 190.9 31.8-9548
Insulin costs (NGN) 5212.8 (5878.8) 3650 1120-30,000
Insulin costs (USD) 33.1 (37.4) 23.2 7.1-190.9
Table 6 Comparison of clinical parameters between persons with type 1 and those with type 2 DM
Variable Type 1 Type 2 DM p
Insulin adherence 22 (71%) 101 (78.3%) 0.3
Self injection of insulin 30 (97%) 120 (93%) 0.7
Self blood glucose monitoring 19 (61%) 71 (55%) 0.5
Mean cost of insulin per month (NGN) 3664.5 (1606.3) 4745.7 (5210.1) 0.04
Mean cost of insulin per month (USD) 23.3 (10) 30.2 (33.2) 0.04
∗Hospitalization frequency for poor glucose control 25 (80.6%) 76 (58.9%) 0.02
∗Proportion of persons with previous hospitalizations for poor glucose control.
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tions and hypoglycemic events, burden of injections,
inconveniences associated with its use [9,10]. The issue
of costs is hardly reported although in sub-Saharan
Africa poor accessibility to healthcare is a problem. In a
Nigerian study on adherence to medications in persons
with DM, the issue of high costs of medication was
brought to the forefront [11].This observation was sup-
ported by the findings in the Diabcare Africa Study
which was carried out in six countries in sub-Saharan
Africa[12]. In Nigeria, the minimum monthly wage is
18,000 naira (120USD), and the mean costs of insulin
for those who paid for their insulin themselves -who
incidentally had type 2 DM- was 5212 (33.1USD). We
deduce that a person on minimum monthly wage
would spend about 29% their monthly income on the
procurement of insulin. In this Report, all Respondents
practiced “out of pocket” payment for healthcosts.
(The large majority of persons attending the govern-
ment hospitals in Nigeria are not on health insurance
schemes). Insulin costs incurred by persons with type
2 DM were however higher than those incurred by
persons with type 1 DM. Reasons for this scenario
may be partly explained by the observation that some
respondents with type 2 DM injected insulin four
times daily and also used insulin analogues which are
more expensive than human insulin. Insulin analoguesFigure 3 Comparison of frequency of daily dosing of insulin in
type 1 and type 2 DM.are not readily accessible in our practice and are pre-
scribed only by Endocrinologists.
The combination of prandial and basal insulin clearly
results in better glycaemic control and less glucose vari-
ability [13].Multiple insulin dosing administration com-
mencement in our patients with DM depends on the
degree of hyperglycemia and the patient’s acceptance of
multiple daily injections. In our practice we observe that
persons with type 2 DM are often more motivated than
those with type 1 DM in the acceptance of usage of mul-
tiple daily insulin injections. Cost and lifestyle limita-
tions are multiple insulin injection related issues of
which patients with type 2 DM are likely to be more
empowered than persons with type 1 DM to take in
their stride. Our findings of multiple daily insulin injec-
tions in persons with type 2 DM are most likely due to
the aforementioned reasons. The health Insurance
scheme is at best sub-optimal in our practice and none
of the patients seen in our clinic on insulin is on a health
insurance scheme.
Insulin adherence is not widely studied in sub-Saharan
Africa and thus factors associated with adherence are
often not objectively substantiated for. We report an in-
sulin adherence rate of 77% and the rates were
comparable- between persons with type 1 and those with
type 2 DM. In a review on insulin adherence in type 2
DM, adherence rates were found to be lower for insulin
use than for OHA use and ranged between 73–86% [14].
The factors that significantly affected insulin adherence
in our Report included previous hospitalization self in-
sulin injecting practices, duration of DM and age. The
Respondents who admitted to previous DM related
hospitalizations obviously did not want a repeat epi-
sode hence tended to adhere to prescribed medications
for DM. Self insulin injection was practised by a great
majority of respondents and this affected insulin ad-
herence positively. We note also that the lesser the
duration of DM, and the older the age of the respond-
ent, the more likely the chances of adherence to insu-
lin therapy. Literacy was not found to have an impact
on adherence and we document comparable adherence
rates between persons who are literate and those with
no form of literacy.
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devices and the reason for this is ready accessibility. The
insulin pens which are more convenient to use are at
present not readily available to most persons with DM
as only a third of the Respondents used them. Continu-
ous subcutaneous insulin infusion as a means of insulin
administration is virtually absent in our practice and
may even prove to be unaffordable even if available.
Hypoglycaemia and weight gain are issues associated
with insulin use and may be obstacles to the use of insu-
lin [15]. In our Study, hypoglycaemia was noted in well
over half of the study subjects whilst weight gain and
skin changes were reported by a third of the respon-
dents. In a Report on insulin omission in women with
type 1 DM, weight gain was noted to be a reason why
31% of the Study participants reported intentionally in-
sulin dose omission [16].
The use of insulin is important to effectively control
the disease process in patients with diabetes mellitus
and insulin adherence has been especially proven to be
associated with good long term metabolic control [17].
We have shown that long term glycaemic control in per-
sons with DM tends to be poorer in persons who show
non adherence to prescribed insulin.
Conclusion
From the foregoing, we note that the factors affecting in-
sulin adherence include modifiable and non modifiable
factors thus adherence interventions might help improve
this all important aspect of healthcare.
Limitation
Categorical endpoints were not used to determine insu-
lin adherence.
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